37-residue peptide derived from human cathelicidin
Cathelicidin LL-37 — evidence
What has been published, classified by the kind of document it is. This is not a protocol, not a score, and not a recommendation for use.
Evidence overview
No evidence records in this file yet.
What we know
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
Regulatory notes
No FDA-approved product
- No approved drug product exists in Drugs@FDA.
- Listed as “Cathelicidin LL-37” on FDA's table of bulk substances nominated for compounding and withdrawn. FDA's published concerns include immunogenicity risk for certain routes, peptide-related impurities and API characterisation, and insufficient safety information.
- FDA's entry also notes nonclinical findings suggesting detrimental effects on male reproduction and that the substance can be protumorigenic in some tissues.
- Not named on the WADA 2026 Prohibited List.
Regulatory status describes how a substance is classified. It is not a safety assessment of any particular material.
No records in this file match the current filter. That is an empty result, not a finding about the compound.
Last reviewed 15 September 2026 · Compiled by Therapept Editorial · How these records are built